Topics

CNS Tumors | Treatment | Chemotherapy | Temozolomide

Home > Publications > Topics > CNS Tumors > Treatment > Chemotherapy > Temozolomide

Lin Y, Deng M, Xu S, Chen C, Ding J.
Post-Marketing Safety of Temozolomide: A Pharmacovigilance Study Based on the Food and Drug Administration Adverse Event Reporting System.
Oncology. 2025 Jan 24:1-9. doi: 10.1159/000542989. PMID: 39864433. Observational study˰ ˍ

Yaacov A, Gillis R, Salim J, Katz D, Asna N, Paldor I, Grinshpun A.
The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management.
Cells. 2025 Dec 29;15(1):57. doi: 10.3390/cells15010057. PMID: 41511341. Review. ˍ